Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens
Personalized cancer vaccines targeting patient-specific neoantigens are a promising cancer treatment modality; however, neoantigen physicochemical variability can present challenges to manufacturing personalized cancer vaccines in an optimal format for inducing anticancer T cells. Here, we developed...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
Nature Research
2020
|